Yes, thank you, Madam Chair.
Thank you to the witnesses today. I have a few things to ask.
First, to Mr. Gagnon, I'm wondering if you could clarify whether you received information on adverse drug reactions here in your practice, or within your organization. The concerns, I imagine, were brought to the attention of Health Canada. As I understood you to say, it was not taken off...or the marketing process was not stopped, which is the function of Health Canada, as opposed to pulling a drug off the market.
Had you heard from other sources in other countries that there were adverse drug reactions, and then made that known? Or was it known and the marketing didn't stop? It wasn't clarified exactly: did you receive that information, or did your members receive that, before you brought it to the attention of Health Canada? Or was this something that you had heard about worldwide?